Home    Help    Cart    Login
Get Free Updates on Industry Research and Analysis!


Search all reports:
 Go 


Pharma and Biotech News


Marketing Services
Interested in marketing your information product through us? Email us at helpdesk AT pharma-reports.com

or call 800-304-0345




Topic Suggestion?


 Item Detail
Item Detail
You're Here: Biotech » Stem Cell



Cord Blood Banks – Why Some Continue to Grow While Others “Flat-Line”

Select Your Format:
Price: $3,495.00
Shipping: US:  $50.00 
Non-US  $70.00
QTY:
Print Order form to pay by check
Capitalizing on Opportunities in Cord Blood Industry Growth
Capitalizing on Opportunities in Cord Blood Industry Growth
BioInformant

Over the past 12 months, the cord blood banking industry has expanded through double digit growth, due to new entrants in the cord blood banking industry as well as revenue growth at existing operations. Deeper analysis reveals that of existing cord blood banks, most fall into one of two “camps,” either experiencing flat-line growth (less than 3% per annum) or substantively building revenue (17% or more per annum).

This finding begs the questions:

- What factors are causing a substantial number of new cord blood banks to open up business? Is it the result of a profit opportunity, advances in therapeutic applications, a social response to more parents being aware of the opportunity to store cord stem cells at birth, or are other factors driving the activity?

- What will be the effect of these new entrants to the cord blood banking industry for existing competitors?

- Perhaps most critically, what are the differences among the cord blood banks that are experiencing flat-line growth versus those that have substantively built revenue over the past 12 months?

In the initial version of this report, "Choices in Cord Blood Banking – Factors Influencing Parental Decision-Making," launched April 2009, an survey of 1,200 expectant parents was used to provide a road-map for how cord blood banks can best communicate and market their services to potential clients. The top-selling report explored the specific reasons that parents elect to store cord blood and what factors influence their decision-making in choosing a specific bank.

This expanded and updated version includes all content from the original report, as well as supplemental analysis of factors that have produced double-digit industry growth over the past year. It provides guidance on how to break through flat-line growth to become a fast-growing competitor within the cord blood industry.

In summary:

Part 1 of the report considers strategic differences between flat-line vs. fast growth cord blood companies.

Part 2 uses proprietary data-derivation techniques to analyze conditions of the Cord Blood Banking Industry.

Part 3 of this report presents findings from an international survey of expectant parents to analyze a complex array of factors involved in the decision to store cord blood.

Key findings of the report include:

- Rates of cord blood banking awareness by gender, income, geographic location, and education

- Sources through which expectant parents learn of cord blood preservation

- Factors influencing private vs. public storage of cord blood

- Price sensitivity and quality expectations

- Approaches for communicating with expectant parents

- Key factors influencing the decision to store cord blood

- Parental responsiveness to health statistics

- Trends in cord blood banking

- Competitive analysis of the cord blood banking industry

- And Much More


Table of Contents



196 pages

Publication Date : January 2010
 Options
Options
Select Your Format:
 Your Price
Your Price
Price: $3,495.00
Shipping: US:  $50.00 Non-US  $70.00
 QTY: 

Print Order form to pay by check


 Related Items
Related Items
Advances in the Stem Cell Industry: The Future Impact of Innovation and an Evaluation of the Commercial Landscape Advances in the Stem Cell Industry: The Future Impact of Innovation and an Evaluation of the Commercial Landscape

An important milestone in the development of stem cell technology occurred in 2007, when researchers induced human cells into a stem cell state using defined genetic factors. These cells are now known as induced pluripotent stem (IPS) cells; they offer an alternative to using embryonic stem cells.  (MORE)
Opportunities in Human Embryonic Stem Cell (hESC) Products Opportunities in Human Embryonic Stem Cell (hESC) Products

Human embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, which is a stage reach 4-5 days post fertilization. They are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body, providing tremendous therapeutic potential. Human ESCs were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R.  (MORE)
 

Return policy: We do accept hard copy books if a reason is included. Electronic products including
CD-ROMs and PDF files are non-returnable/non-refundable due to the duplicable nature of these products.

To market your reports, contact us at 800-304-0345 or email
Helpdesk AT PharmaReports DOT com